Literature DB >> 18287881

Nitric oxide does not downregulate Rho-kinase (ROCK-2) expression in rat coronary endothelial cells.

R Nalan Tiftik1, Ayşe Erol, Mehtap G Cnar, Havva Kubat, Mustafa Ark, Sibel Ulker, Kansu Büyükafşar.   

Abstract

Rho kinase (ROCK) and nitric oxide (NO) are important targets in cardiovascular diseases. Therefore, we investigated the possible influence of NO on Rho kinase (ROCK-2 isoform) expressions in cultured rat coronary microvascular endothelial cells. The cells were isolated from Wistar rats on a Langendorff system, and were incubated overnight (approximately 16 h) with an NO generator, A-23187 (10 to 10 M), NO donors, such as sodium nitroprusside (10 to 10 M), glyceryl trinitrate (10 to 10 M), 2,2'-(hydroxynitrosohydrazono)bis-ethanimine (10 to 10 M), and NaNO2 (10 to 10 M) or a nitric oxide synthase (NOS) inhibitor, N-nitro-L-arginine methylester (2 x 10 M), or two ROCK inhibitors, (+)-(R)-trans-4-(1-aminoethyl)- N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride monohydrate (Y-27632, 10 M) and fasudil (10 M) in the absence or presence of thrombin (4 U/mL). ROCK-2 and endothelial NOS (eNOS) expressions were detected by Western blotting. Moreover, nitrite/nitrate levels were detected by Griess method in the presence of the ROCK inhibitors. The NO donors and the NO generator had no significant effects on ROCK-2 expression. Y-27632 and fasudil did not alter eNOS expression and NO production. Nitrite/nitrate levels were 4.4 +/- 0.32 microM in control and 4.0 +/- 0.93 microM and in Y-27632 group. These results demonstrate that prolong NO donation could not suppress the expression of ROCK-2 protein, and the ROCK inhibitor did not change e-NOS expression and NO production in the cultured rat coronary microvascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287881     DOI: 10.1097/FJC.0b013e31815e4089

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage.

Authors:  Guang Jian Liu; Zheng Jun Wang; Yun Fu Wang; Li Li Xu; Xiao Ling Wang; Yong Liu; Guo Jun Luo; Guo Hou He; Yan Jun Zeng
Journal:  Eur J Clin Pharmacol       Date:  2011-08-12       Impact factor: 2.953

2.  The role of Rho/Rho-kinase pathway and the neuroprotective effects of fasudil in chronic cerebral ischemia.

Authors:  Ya-Yun Yan; Xiao-Ming Wang; Yan Jiang; Han Chen; Jin-Ting He; Jing Mang; Yan-Kun Shao; Zhong-Xin Xu
Journal:  Neural Regen Res       Date:  2015-09       Impact factor: 5.135

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.